Cargando…

Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study

Detalles Bibliográficos
Autores principales:	Caruso, Arnaldo, Iaria, Marialuisa, Caccuri, Francesca, Giagulli, Cinzia, Fiorentini, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220871/ http://dx.doi.org/10.1186/1471-2334-14-S2-O6

Ejemplares similares

Opposite Effects of HIV-1 p17 Variants on PTEN Activation and Cell Growth in B Cells
por: Giagulli, Cinzia, et al.
Publicado: (2011)

Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17
por: Caccuri, Francesca, et al.
Publicado: (2016)

HIV-1 matrix protein p17 and its variants promote human triple negative breast cancer cell aggressiveness
por: Caccuri, Francesca, et al.
Publicado: (2017)

A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17
por: Giagulli, Cinzia, et al.
Publicado: (2017)

B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation
por: Giagulli, Cinzia, et al.
Publicado: (2020)

Emergence of Exhausted B Cells in Asymptomatic HIV-1-Infected Patients Naïve for HAART is Related to Reduced Immune Surveillance
por: Fogli, Manuela, et al.
Publicado: (2012)

Role of Autophagy in Von Willebrand Factor Secretion by Endothelial Cells and in the In Vivo Thrombin-Antithrombin Complex Formation Promoted by the HIV-1 Matrix Protein p17
por: Bugatti, Antonella, et al.
Publicado: (2020)

The Synthetic Dipeptide Pidotimod Shows a Chemokine-Like Activity through CXC Chemokine Receptor 3 (CXCR3)
por: Caccuri, Francesca, et al.
Publicado: (2019)

Human Metapneumovirus Establishes Persistent Infection in Lung Microvascular Endothelial Cells and Primes a Th2-Skewed Immune Response
por: Bugatti, Antonella, et al.
Publicado: (2020)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Full-length HIV-1 immunogens induce greater T lymphocyte responses to conserved epitopes than conserved-region-only HIV-1 immunogens in monkeys
por: Stephenson, KE, et al.
Publicado: (2012)

Binding to PI(4,5)P(2) is indispensable for secretion of B-cell clonogenic HIV-1 matrix protein p17 variants
por: Bugatti, Antonella, et al.
Publicado: (2021)

Antiretroviral treatment and association with prematurity in perinatal HIV-exposed children
por: Tudor, Ana Maria, et al.
Publicado: (2014)

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients
por: Wimmers, Florian, et al.
Publicado: (2017)

Antiretroviral drug resistance and viral tropism in HIV-1 CRF06_cpx infected patients failing antiretroviral (ARV) therapy
por: Pauskar, Merit, et al.
Publicado: (2014)

Antiretroviral treatment in adult ethnobotanical intravenous drug users recently infected with HIV
por: Popa, Ionuț Cristian, et al.
Publicado: (2014)

International perspectives on adherence and resistance to HIV antiretroviral therapy
por: Bangsberg, D
Publicado: (2010)

Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma
por: Tusé, Daniel, et al.
Publicado: (2015)

First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020
por: Fiorentini, Simona, et al.
Publicado: (2021)

Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients
por: Seclén, E, et al.
Publicado: (2010)

OA031-03. Increased regulatory T cell frequency and HIV-1 specific suppression after therapeutic vaccination of HIV-infected patients on antiretroviral therapy
por: Macatangay, BC, et al.
Publicado: (2009)

HIV replication and evolution in patients on highly active antiretroviral therapy
por: Siliciano, Robert F
Publicado: (2006)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

The challenges of managing antiretroviral treatment in children perinatally infected with HIV in Romania
por: Cibea, Alina, et al.
Publicado: (2014)

Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications
por: Bugatti, Antonella, et al.
Publicado: (2019)

Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection
por: Lodi, S, et al.
Publicado: (2010)

Modest deviations from optimal adherence to antiretroviral therapy promote residual HIV-1 replication in the absence of virological rebound in plasma
por: Pasternak, Alexander O, et al.
Publicado: (2011)

Immunodynamics of Th17 cells in HIV-1 subtype ‘C’ infection
por: Vajpayee, Madhu, et al.
Publicado: (2012)

OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers
por: Vasan, S, et al.
Publicado: (2009)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study
por: May, M, et al.
Publicado: (2012)

OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission
por: Lingappa, JR, et al.
Publicado: (2009)

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
por: Zani, Alberto, et al.
Publicado: (2021)

Metabolic syndrome, insulin resistance and the risk of cardiovascular disease in HIV patients undergoing antiretroviral therapy
por: Tilişcan, Cătălin, et al.
Publicado: (2013)

Correlation between inflammatory biomarkers and metabolic disorders in HIV infected patients undergoing antiretroviral therapy
por: Mihăilescu, Raluca, et al.
Publicado: (2013)

HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide
por: Caccuri, Francesca, et al.
Publicado: (2022)

Mother to child transmission (MTCT) of HIV - almost a thing of the past? A cohort study of HIV positive women starting antiretroviral drugs in pregnancy
por: Leonard, Hugh A, et al.
Publicado: (2014)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

In vivo targeting of HIV gag to dendritic cells in combination with poly ICLC is safe and immunogenic in healthy volunteers
por: Caskey, M, et al.
Publicado: (2012)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8s396gb2hsonj7d7ioaup05i9o